Adriaan H. de Wilde

Adriaan H. de Wilde

Auto-generated profile, based on publicly available information

Adriaan H. de Wilde

VectorY Therapeutics B.V., Science Park 408, Amsterdam 1098 XH, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LSLaura Solforosi
Laura Solforosi
HKHarmjan Kuipers
Harmjan Kuipers
MJMandy Jongeneelen
Mandy Jongeneelen
SHSietske K. Rosendahl Huber
Sietske K. Rosendahl Huber
JLJoan E.M. van der Lubbe
Joan E.M. van der Lubbe
RZRoland Zahn
Roland Zahn
Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to control the ongoing pandemic. While single-dose vaccine regimens would provide multiple advantages, two doses may improve the magnitude and durability of immunity and protective efficacy. We assessed one- and two-dose regimens of the Ad26.COV2.S vaccine candidate in adult and aged nonhuman primates (NHPs). A two-dose Ad26.COV2.S regimen induced higher peak binding and neutralizing antibody responses compared with a single dose. In one-dose regimens, neutralizing antibody responses were stable for at least 14 wk, providing an early indication of durability. Ad26.COV2.S induced humoral immunity and T helper cell (Th cell) 1–skewed cellular responses in aged NHPs that were comparable to those in adult animals. Aged Ad26.COV2.S-vaccinated animals challenged 3 mo after dose 1 with a SARS-CoV-2 spike G614 variant showed near complete lower and substantial upper respiratory tract protection for both regimens. Neutralization of variants of concern by NHP sera was reduced for B.1.351 lineages while maintained for the B.1.1.7 lineage independent of Ad26.COV2.S vaccine regimen.

2 June 2026 in Trends in Biotechnology
Verified
Journal Article
Open access
LJLinda A. de Jong
Linda A. de Jong
JWJelmer Willems
Jelmer Willems
AWAdriaan H. de Wilde
Adriaan H. de Wilde
MSMels Schrama
Mels Schrama
BSBarbara P. Sanders
Barbara P. Sanders
Gorben PijlmanGorben Pijlman
Gorben Pijlman
In vivo gene therapy is rapidly advancing to treat patients with a wide range of genetic disorders. Recombinant adeno-associated virus (rAAV) vectors provide long-term gene expression, low immunogenicity, and adaptable tissue tropism. Production of rAAV in insect cells with the Baculovirus Expression Vector System currently depends on infection with multiple baculoviruses encoding AAV genes Rep, Cap, and the therapeutic gene. In this research article, we present simplified rAAV production using a single baculovirus vector with improved genetic stability, called BAC6Rep, with AAV Rep locked into the baculovirus genome. Robust AAV Rep and Cap expression was maintained upon serial passaging, and high rAAV yields (up to 3.5e11 genome copies/ml) were obtained at high and low multiplicities of infection. Next-generation sequencing revealed a significantly improved genetic stability of BAC6Rep, which can now be used as a plug-in hybrid vector for flexible insertion of different AAV Cap and gene of interest tailored to the therapeutic target.